Jove
Visualize
Contact Us

Related Concept Videos

Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Encephalopathy retarded by carbon monoxide].

Revista de neurologia·2002
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 15, 2026

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
06:58

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing

Published on: January 24, 2020

[Memory, fluency, and orientation: a five-minute screening test for cognitive decline].

C Delgado Derio1, S Guerrero Bonnet, M Troncoso Ponce

  • 1Departamento de Neurología y Neurocirugía, Hospital Clínico Universidad de Chile, Santiago, Chile; Dirección de Investigación Clínica, Hospital Clínico Universidad de Chile, Santiago, Chile.

Neurologia (Barcelona, Spain)
|December 19, 2012
PubMed
Summary
This summary is machine-generated.

A new 5-minute cognitive impairment (CI) screening test, MEFO, effectively differentiates between no cognitive impairment, mild cognitive impairment, and dementia. This rapid screening tool shows high validity, aiding early detection of cognitive decline.

Keywords:
ChileCognitive impairment screeningCribado de deterioro cognitivoDemenciasDementiaEspañolSpanish

More Related Videos

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Related Experiment Videos

Last Updated: May 15, 2026

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
06:58

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing

Published on: January 24, 2020

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Area of Science:

  • Neurology
  • Gerontology
  • Psychometrics

Background:

  • Cognitive impairment (CI) prevalence is projected to double in 20 years, highlighting the need for early detection.
  • Accurate and efficient screening tools are crucial for timely diagnosis and intervention.

Purpose of the Study:

  • To validate a novel, rapid 5-minute screening test for cognitive impairment.
  • To compare the diagnostic accuracy of the MEFO test with the established MMSE.

Main Methods:

  • Recruited 214 adults (≥60 years) from memory clinics and the community in Santiago, Chile.
  • Categorized participants into No CI (NCI), Mild CI (MCI), and Dementia (DS) based on clinical examination.
  • Assessed the validity of the MEFO test (memory, fluency, orientation) against the Mini-Mental State Examination (MMSE).

Main Results:

  • The MEFO test accurately differentiated between NCI, MCI, and DS groups (AUC 0.97 for NCI vs. dementia).
  • MEFO demonstrated superior discrimination between MCI and NCI groups (AUC 0.80) compared to MMSE (AUC 0.73).
  • MEFO achieved 86% sensitivity and 96% specificity for detecting dementia at a 6/7 cut-off.

Conclusions:

  • The MEFO test is a valid and reliable tool for discriminating cognitive impairment severity.
  • MEFO offers comparable validity to MMSE but is more effective for identifying MCI and significantly faster.
  • This rapid screening test supports early detection of cognitive decline in older adults.